semaglutide and prostate cancer Emerging mechanisms of enzalutamide resistance in Prostate Cancer Treatment (PDQ®)–Patient Version

Clinical Capsules: Semaglutide Becomes the First ORAL GLP-1 Approved for Weight Loss A new oral option is changing the GLP-1 landscape for weight loss, along with raising questions about efficacy, dosing, and when switching products makes sense

The strongest predictor of a good final result across these trials was an early response, with people who lost at least 5% of body weight by week 12 going on to the best outcomes

PLoS ONE 14 , e0220966 (2019)

Some research shows it can boost performance by as much as a whopping 11% over a period of 4-6 months

doi: 10.1016/j.yexcr.2017.09.018 70 ZhaoHWangLWeiRXiuDTaoMKeJet al